Synthetic antimicrobial peptidomimetics with therapeutic potential

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4306-4314

  Haug, Bengt Erik ^a,b   Stensen, Wenche ^a,c   Kalaaji, Manar ^a   Rekdal, Øystein ^a,c   Svendsen, John S ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c LYTIX BIOPHARMA AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BILAYER MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG SELECTIVITY; DRUG SYNTHESIS; ERYTHROCYTE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE VESICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN DEGRADATION; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOMIMETIC MATERIALS; BLOOD; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECTROMETRY, FLUORESCENCE;

EID: 47749116861     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701600a     Document Type: Article

References (46)

1. Hancock, R. E. W. The end of an era. Nat. Rev. Drug Discovery 2007, 6, 28.
2. Mwangi, M. M.; Wu, S. W.; Zhou, Y.; Sieradzki, K.; Lencastre, H. d.; Richardson, P.; Bruce, D.; Rubin, E.; Myers, E.; Siggia, E. D.; Tomasz, A. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 9451-9456.
3. A joint focus on the need for new antibacterials was recently featured by the journals Nature Biotechnology and Nature Reviews Drug Discovery. For Web site, see http://www.nature.com/focus/antibacterials/ index.html.
4. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
5. Hancock, R. E. W.; Scott, M. G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8856-8861.
6. Raj, P. A.; Dentino, A. R. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol. Lett. 2002, 206, 9-18.
7. For a complete and updated list, see http://aps.unmc.edu/AP/main.php.
8. Ludtke, S.; He, K.; Huang, H. Membrane thinning caused by magainin 2. Biochemistry 1995, 34, 16764-16769.
9. Hancock, R. E. W.; Bell, A. Antibiotic uptake into Gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7, 713-720.
10. Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1999, 1462, 55-70.
11. Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1999, 1462, 1-10.
12. Huang, H. W. Action of antimicrobial peptides: two-state model. Biochemistry 2000, 39, 8347-8352.
13. Hancock, R. E. W.; Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 1999, 43, 1317-1323.
14. Wu, M. H.; Maier, E.; Benz, R.; Hancock, R. E. W. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999, 38, 7235-7242.
15. McPhee, J. B.; Hancock, R. E. W. Function and therapeutic potential of host defence peptides. J. Pept. Sci. 2005, 11, 677-687.
16. Jenssen, H.; Hamill, P.; Hancock, R. E. W. Peptide Antimicrobial Agents. Clin. Microbiol. Rev. 2006, 19, 491-511.
17. Haug, B. E.; Strøm, M. B.; Svendsen, J. S. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr. Med. Chem. 2007, 14, 1-18.
18. Strøm, M. B.; Haug, B. E.; Skar, M. L.; Stensen, W.; Stiberg, T.; Svendsen, J. S. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 2003, 46, 1567-1570.
19. Haug, B. E.; Svendsen, J. S. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. Sci. 2001, 7, 190-196.
20. Haug, B. E.; Skar, M. L.; Svendsen, J. S. Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J. Pept. Sci. 2001, 7, 425-432.
21. Haug, B. E.; Andersen, J.; Rekdal, Ø.; Svendsen, J. S. Synthesis of a 2-arylsulfonylated tryptophan: the antibacterial activity of bovine lactoferricin peptides containing Trp(2-Pmc). J. Pept. Sci. 2002, 8, 307-313.
22. Haug, B. E.; Stensen, W.; Stiberg, T.; Svendsen, J. S. Bulky nonproteinogenic amino acids permit the design of very small and effective cationic antibacterial peptides. J. Med. Chem. 2004, 47, 4159-4162.
23. Haug, B. E.; Stensen, W.; Svendsen, J. S. Application of the Suzuki-Miyaura cross-coupling to increase antimicrobial potency generates promising novel antibacterials. Bioorg. Med. Chem. Lett. 2007, 17, 2361-2364.
24. Wünsch, E.; Jaeger, E.; Kisfaludy, L.; Löw, M. Side reactions in peptide synthesis: tert-butylation of tryptophan. Angew. Chem., Int. Ed. Engl. 1977, 16, 317-318.
25. Löw, M.; Kisfaludy, L.; Jaeger, E.; Thamm, P.; Knof, S.; Wünsch, E. Direct tert-butylation of tryptophan: preparation of 2,5,7-tri-tert-butyltryptophan. Hoppe-Seyler's Z. Physiol. Chem. 1978, 359, 1637-1642.
26. Vogel, H. J.; Schibli, D. J.; Jing, W.; Lohmeier-Vogel, E. M.; Epand, R. F.; Epand, R. M. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem. Cell Biol. 2002, 80, 49-63.
27. Lehrer, R. I.; Barton, A.; Ganz, T. Concurrent assessment of inner and outer membrane permeabilization and baceriolysis in E. coli by multiple-wavelength spectrophotometry. J. Immunol. Methods 1988, 108, 153-158.
28. Braumann, T. Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. J. Chromatogr. 1986, 373, 191-225.
29. Hancock, R. E. W.; Rozek, A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol. Lett. 2002, 206, 143-149.
30. Hancock, R. E. W.; Sahl, H.-G. Antimicrobial and host-defence peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24, 1551-1557.
31. Shai, Y.; Oren, Z. From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 2001, 22, 1629-1641.
32. Friecrich, C. L.; Moyles, D.; Beveridge, T. J.; Hancock, R. E. W. Antibacterial action of structurally diverse cationic peptides on Gram-positive bacteria. Antimicrob. Agents Chemother. 2000, 44, 2086-2092.
33. Sader, H. S.; Fedler, K. A.; Rennie, R. P.; Stevens, S.; Jones, R. N. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob. Agents Chemother. 2004, 48, 3112-3118.
34. Sitaram, N.; Nagaraj, R. Interaction of antimicrobial peptides with biological and model membranes: structural and charge requirements for activity. Biochim. Biophys. Acta 1999, 1462, 29-54.
35. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000, 406, 775-781.
36. Kang, J. H.; Lee, M. K.; Kim, K. L.; Hahm, K.-S. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int. J. Pept. Protein Res. 1996, 48, 357-363.
37. Kondejewski, L. H.; Lee, D. L.; Jelokhani-Niaraki, M.; Farmer, S. W.; Hancock, R. E. W.; Hodges, R. S. Optimization of microbial specificity in cyclic peptides by modulation of hydrophobicity within a defined structural framework. J. Biol. Chem. 2002, 277, 67-74.
38. The D-Tbt was prepared by alkylation of the unnatural enantiomer of tryptophan.
39. Fernandez-Lopez, S.; Kim, H.-S.; Choi, E. C.; Delgado, M.; Granja, J. R.; Khasanov, A.; Kraehenbuehl, K.; Long, G.; Weinberger, D. A.; Wilcoxen, K. M.; Ghadiri, M. R. Antibacterial agents based on the cyclic D,L-α- peptide architecture. Nature 2001, 412, 452-455.
40. Sajgo, M.; Löw, M. Enzymatic digestibility of peptides containing tert-butyltryptophan residues. Hoppe-Seyler's Z. Physiol. Chem. 1979, 360, 9-12.
41. Svenson, J.; Brandsdal, B. O.; Stensen, W.; Svendsen, J. S. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J. Med. Chem. 2007, 50, 3334-3339.
42. Keller, O.; Keller, W. E.; van Look, G.; Wersin, G. tert-Butoxycarbonylation of amino acids and their derivatives: N-tert-butoxycarbonyl-L-phenylalanine. Org. Synth. 1985, 63, 160-170.
43. Löw, M.; Kisfaludy, L.; Sohár, P. tert-Butylation of the tryptophan indole ring during the removal of the tert-butyloxycarbonyl group. Hoppe-Seyler's Z. Physiol. Chem. 1978, 359, 1643-1651.
44. Mayer, L. D.; Hope, M. J.; Cullis, P. R. Vesicles of variable size produced by a rapid extrusion procedure. Biochim. Biophys. Acta 1986, 858, 161-168.
45. Eibl, H.; Lands, W. E. A new, sensitive determination of phosphate. Anal. Biochem. 1969, 30, 51-57.
46. Dathe, M.; Schümann, M.; Wieprecht, T.; Winkler, A.; Beyermann, M.; Krause, E.; Matsuzaki, K.; Murase, O.; Bienert, M. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996, 35, 12612-12622.